Thomas Andrew Wynn

This inventor holds 30 USPTO granted patents and 11 published patent applications, plus 5 CIPO patents and 5 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Alkermes Pharma Ireland Limited, Alkermes, Inc.. Active years: 2014-2025.

USPTO Granted Patents = 30 (Patent Applications = 11)

% Patents Active = 86.7

CIPO Patents = 5 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 7)

Average Co-Inventor Count = 4.5

ph-index = 8

Forward Citations = 208(Granted Patents)

Company Filing History:

28 out of 164

Alkermes Pharma Ireland Limited

Years Active: 2014-2025

Loading Chart...

Areas of Expertise:

Prodrugs

Fumarates

Depressive Symptoms

Pain Treatment

Thiophene Compounds

Long-Acting Injectables

Thienothiophene Compounds

Naphthylenyl Compounds

Morphinan Analogues

Sulfonamide Prodrugs

Sulfinamide Prodrugs

Compounds

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12257249 - Methods for treating depressive symptoms (2025-03-25),

2. 12076306 - Prodrugs of fumarates and their use in treating various diseases (2024-09-03),

3. 11905298 - Prodrugs of fumarates and their use in treating various diseases (2024-02-20),

4. 11679092 - Prodrugs of fumarates and their use in treating various diseases (2023-06-20),

5. 11534436 - Methods for treating depressive symptoms (2022-12-27),

6. 11230548 - Prodrugs of fumarates and their use in treating various diseases (2022-01-25),

7. 11180455 - Compounds for the treatment of pain (2021-11-23),

8. 11083703 - Prodrugs of fumarates and their use in treating various diseases (2021-08-10),

9. 10975099 - Thiophene compounds for long-acting injectable compositions and related methods (2021-04-13),

10. 10807995 - Thienothiophene compounds for long-acting injectable compositions and related methods (2020-10-20),

11. 10799496 - Naphthylenyl compounds for long-acting injectable compositions and related methods (2020-10-13),

12. 10752592 - Morphan and morphinan analogues, and methods of use (2020-08-25),

13. 10736890 - Methods for treating depressive symptoms (2020-08-11),

14. 10604489 - Compounds for the treatment of pain (2020-03-31),

15. 10596140 - Prodrugs of fumarates and their use in treating various diseases (2020-03-24),

Title: Thomas Andrew Wynn: A Pioneer in Pharmaceutical Innovations

Introduction

Thomas Andrew Wynn, based in Lexington, MA, is a notable inventor with a significant contribution to the field of pharmaceuticals. With a remarkable portfolio of 29 patents, Wynn has been instrumental in the development of innovative treatments aimed at addressing various neurological diseases.

Latest Patents

Among his latest inventions are two related patents titled "Prodrugs of Fumarates and Their Use in Treating Various Diseases." These patents detail compounds of formula (I) and their corresponding pharmaceutical compositions. The inventions provide vital methods for treating neurological diseases, particularly multiple sclerosis, showcasing Wynn’s commitment to advancing medical science.

Career Highlights

Throughout his impressive career, Wynn has collaborated with prominent companies in the pharmaceutical sector, including Alkermes Pharma Ireland Limited and Alkermes, Inc. His work at these institutions has enabled the translation of innovative research into viable therapeutic solutions.

Collaborations

Wynn has had the privilege of working alongside esteemed colleagues in his field, including Christopher P. Hencken and Carlos N. Sanrame. These collaborations have fostered a rich environment for creativity and innovation, driving forward the development of cutting-edge treatments.

Conclusion

In summary, Thomas Andrew Wynn stands out as a significant figure in the realm of pharmaceutical innovations. His extensive patent portfolio and collaborations reflect his dedication to improving healthcare outcomes through inventive solutions. As ongoing research continues to evolve, Wynn’s contributions will undoubtedly play a vital role in shaping the future of treatments for neurological diseases.